ArticleFrontiers in medicine2026
Precise discrimination of mycobacterial pulmonary diseases via multimodal machine learning integrating chest CT and clinical markers.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Differentiating Methods: This retrospective study enrolled 102 patients with microbiologically confirmed mycobacterial lung disease, including 53 patients with MTB-LD and 49 patients with NTM-LD. We developed and validated an interpretable multimodal machine-learning framework integrating clinical symptoms, hematological biomarkers, and high-resolution computed tomography (HRCT) features. Three representative classifiers, including k-nearest neighbors, logistic regression, and random forest, were used to evaluate the discriminative contribution of different feature modalities. Results: Multimodal integration of HRCT, clinical, and laboratory features showed better discriminative performance than single-modality approaches. Among the three representative classifiers, the random forest model achieved the best hold-out test performance, with an AUC of 0.92, sensitivity of 0.89, specificity of 0.93, and F1-score of 0.90. Key predictive contributors included cystic bronchiectasis, tree-in-bud sign, fever, and selected laboratory biomarkers. Discussion: These findings suggest that routinely available multimodal clinical data may provide preliminary decision support for MTB-LD/NTM-LD differentiation. However, the proposed framework should be regarded as an exploratory decision-support tool, and external validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.